Dr. Thierry Jahan on CRS-207 With Chemotherapy in Mesothelioma

Thierry Jahan, MD
Published: Thursday, Apr 14, 2016




Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of the immunotherapy CRS-207 with chemotherapy as a treatment for patients with malignant pleural mesothelioma (MPM). CRS-207 is a strain of Listeria that contains 2 gene deletions to diminish its pathogenicity. The bacterium has also been engineered to express mesothelin, which is expressed on mesothelioma cells. 

Mesothelioma is a very difficult disease to treat, says Jahan. Chemotherapy, which is the standard of care, yields between a 20% and 40% response rate, with a median survival of about 1 year.

In a phase Ib study, the combination of CRS-207 with chemotherapy demonstrated a 94% disease control rate and a 59% response rate in patients with MPM, said Jahan. Median progression-free survival was 8.5 months. The combination was well-tolerated, with temperature spikes and rigors as the primary adverse events.

<<< View more from the 2016 European Lung Cancer Conference




Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of the immunotherapy CRS-207 with chemotherapy as a treatment for patients with malignant pleural mesothelioma (MPM). CRS-207 is a strain of Listeria that contains 2 gene deletions to diminish its pathogenicity. The bacterium has also been engineered to express mesothelin, which is expressed on mesothelioma cells. 

Mesothelioma is a very difficult disease to treat, says Jahan. Chemotherapy, which is the standard of care, yields between a 20% and 40% response rate, with a median survival of about 1 year.

In a phase Ib study, the combination of CRS-207 with chemotherapy demonstrated a 94% disease control rate and a 59% response rate in patients with MPM, said Jahan. Median progression-free survival was 8.5 months. The combination was well-tolerated, with temperature spikes and rigors as the primary adverse events.

<<< View more from the 2016 European Lung Cancer Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x